William Blair & Company
RNAC icon

William Blair & Company’s Cartesian Therapeutics RNAC Stock Holding History

William Blair & Company’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-834
Closed -$17.2K – 1841
2023
Q4 		$17.2K Hold
834
– – ﹤0.01% 1681
2023
Q3 		$26.5K Hold
834
– – ﹤0.01% 1655
2023
Q2 		$28K Hold
834
– – ﹤0.01% 1667
2023
Q1 		$34.8K Hold
834
– – ﹤0.01% 1631
2022
Q4 		$28.3K Hold
834
– – ﹤0.01% 1645
2022
Q3 		$41K Hold
834
– – ﹤0.01% 1623
2022
Q2 		$33K Hold
834
– – ﹤0.01% 1677
2022
Q1 		$31K Buy
834
+336
+67% +$21K ﹤0.01% 1755
2021
Q4 		$49K Buy
+498
New +$53.6K ﹤0.01% 1782
2020
Q2 		– Sell
-667
Closed -$48K – 1736
2020
Q1 		$48K Buy
+667
New +$64.4K ﹤0.01% 1396

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair & Company's RNAC Position: Q1 2024 in Review

William Blair & Company sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 834 shares — an estimated $17.2K sold.

William Blair & Company first reported a position in RNAC in Q1 2020 and held it in 10 quarters. The position peaked at $49K in Q4 2021. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • William Blair & Company reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • William Blair & Company sold 834 Cartesian Therapeutics shares in Q1 2024, an estimated $17.2K.
  • William Blair & Company first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 10 quarters.
  • William Blair & Company's Cartesian Therapeutics position peaked at $49K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on William Blair & Company's 13F filing for Q1 2024, filed 9 May 2024.